Cancer incidence and mortality rates are increasing annually. Treatment with surgery,
chemotherapy and radiation therapy (RT) is unsatisfactory because many patients have …

Tumor resistance to therapy modalities is one of the major challenges to the eradication of
cancer cells and complete treatment. Tumor includes a wide range of cancer and non …

Malignant pleural effusion (MPE) remains a treatment bottleneck in advanced lung cancer,
due to its complicated microenvironments and “cold” immunity. Therefore, the search for …

Breast cancer is considered the second-leading cancer after lung cancer and is the most
prevalent cancer among women globally. Currently, cancer immunotherapy via vaccine has …

About 85% of patients with colorectal cancer (CRC) have the non-microsatellite instability-
high (non-MSI-H) subtype, and many cannot benefit from immune checkpoint blockade. A …

Cancer is one of the leading causes of morbidity and death worldwide, making it a serious
global health concern. Chemotherapy, radiotherapy, and surgical treatment are the most …

Background Considering the narrow immune response spectrum of a single epitope, and
the nanoparticles (NPs) as a novel adjuvant can achieve efficient delivery of antigenic …

Peptides exhibit various biological activities, including biorecognition, cell targeting, and
tumor penetration, and can stimulate immune cells to elicit immune responses for tumor …

Vaccines based on tumour‐specific antigens are a promising approach for immunotherapy.
However, the clinical efficacy of tumour‐specific antigens is still challenging. Twelve …

In the present scenario, the role of the peptide as a targeting moiety is enhanced in different
types of cancer treatment which have biological actions based on their properties of …